From the Research
Ceftriaxone is the preferred third-generation cephalosporin for treating UTIs in patients with G6PD deficiency, given its safety profile and effectiveness in this population, as supported by general medical knowledge and the lack of specific contraindications in the provided evidence 1, 2, 3, 4, 5. The typical dosage of ceftriaxone is 1-2 grams intravenously or intramuscularly once daily for 7-14 days, depending on infection severity. Key considerations when treating UTIs in patients with G6PD deficiency include:
- Avoiding known triggers of hemolysis such as fava beans, certain antimalarials, sulfonamides, nitrofurantoin, and other oxidative medications.
- Using cephalosporins, which do not trigger hemolytic reactions in G6PD-deficient individuals.
- Considering alternative third-generation cephalosporins like cefotaxime (1-2g IV every 8 hours) and ceftazidime (1-2g IV every 8-12 hours) if ceftriaxone is not suitable.
- Transitioning to oral therapy with options like cefdinir (300mg twice daily) or cefpodoxime (100-200mg twice daily) for 7-14 days total treatment duration. It is essential to prioritize the patient's safety and adjust the treatment plan according to their specific needs and medical history, ensuring the best possible outcome in terms of morbidity, mortality, and quality of life.